Royalty Report: Drugs, Therapeutic, Cancer – Collection: 160661

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Therapeutic
  • Cancer
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 160661

License Grant
Licensor hereby grants to Licensee an option to obtain an exclusive license with respect to each Licensor Product, exercisable on a product-by-product and country-by-country basis.  Licensee shall exercise its License Option by delivering to Licensor, within the time period, a written notice of exercise specifying the Licensor Product and the country or countries as to which the License Option is exercised. A License Agreement for such Licensor Product shall be deemed to be effective in such country or countries as of the date of such notice of exercise, without the necessity of any additional action by the parties.
License Property
The following compounds have been selected as the initial Licensor Products as of the date hereof: (i) Tazarotene (oral), (ii) Memantine, (iii) AGN 4310 and (iv) a compound to be selected from the RAR alpha-selective agonist class of retinoid compounds for the treatment of various cancers.

Licensor Product shall mean any dosage form of a compound which is the subject of research and development as a potential human pharmaceutical product which has been recommended by Licensee and accepted by Licensors Board of Directors for development as such under the Research and Development Agreement. Such recommendations may be made on a Field of Use basis. The following compounds have been selected as the initial Licensor Products as of the date hereof: (i) Tazarotene (oral), (ii) Memantine, (iii) AGN 4310 and (iv) a compound to be selected from the RAR alpha-selective agonist class of retinoid compounds for the treatment of various cancers.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 160660

License Grant
Licensor hereby grants to Licensee a sublicense to use the Licensee Technology and the Developed Technology solely for the purpose of conducting the activities contemplated hereunder.  Licensor desires that Licensee perform, on behalf of Licensor, research and development activities directed toward the research and development of Licensor Products and related activities.  Licensor has been formed for the purpose of research and developing human pharmaceutical products, including products using Licensee Technology and commercializing such products, most likely through licensing to Licensee.
License Property
Licensee Product shall mean any dosage form of a compound which is the subject of research and development as a potential human pharmaceutical product which has been recommended by Licensee and accepted by Licensors Board of Directors for development as such under this Agreement. Such recommendations may be made on a Field of Use basis. The following compounds have been selected as the initial Licensor Products as of the date hereof: (i) Tazarotene (oral), (ii) Memantine, (iii) AGN 4310 and (iv) a compound to be selected from the RAR alpha-selective agonist class of retinoid compounds for the treatment of various cancers.

Licensee Technology shall mean all Proprietary Rights licensed and/or sublicensed by Licensee and/or its Affiliates pursuant to the Technology License Agreement.

Developed Technology shall mean Proprietary Rights that (a) are first generated, conceived or reduced to practice, as the case may be, by Licensee or by any third party in the course of performing activities undertaken pursuant to this Agreement or (b) are, in any manner, acquired by, or otherwise obtained on behalf of, Licensor during the term of this Agreement from persons other than Licensee and are necessary or useful to the research, development or commercialization of Licensor Products or Pre-Selection Products.

Therapeutic Agent shall mean a drug, protein, peptide, gene, compound or other pharmaceutically active ingredient.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 219094

License Grant
In June 2016, the Company executed an agreement with Licensee, a French public company, which gave the Company the option to license Validive (clonidine mucobuccal tablet), a mucoadhesive tablet of clonidine based on the Lauriad mucoadhesive technology to potentially treat severe oral mucositis in patients undergoing treatment for head and neck cancers.  On September 8, 2017, pursuant to the license option agreement, the Company exercised the option to license Validive.  The exercise of the option assigns all of Licensee’s rights to the Validive intellectual property to the Company, which allows the Company to commence the planning of the Phase III clinical trial in severe oral mucositis.
License Property
Validive (clonidine mucobuccal tablet), a mucoadhesive tablet of clonidine based on the Lauriad mucoadhesive technology to potentially treat severe oral mucositis in patients undergoing treatment for head and neck cancers.

Mucositis is the painful inflammation and ulceration of the mucous membranes lining the digestive tract, usually as an adverse effect of chemotherapy and radiotherapy treatment for cancer.

Field of Use
This agreement pertains to the drug industry relating to oral mucositis in patients undergoing treatment for head and neck cancers.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.